Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences
BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines
Bristol Myers Squibb (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences.
The expanded Vera Rubin infrastructure will give BMS’s scientific and computational teams access to a step-change in both computational power and efficiency, with the Vera Rubin architecture delivering up to ten times greater performance per megawatt than its predecessor, enabling BMS to pursue larger and more sophisticated AI workloads without a proportional increase in energy consumption.
